A number of clinical studies have illustrated that pretreatment levels of folate and homocysteine are predictive for both tumour response and toxicity (low folate levels are associated with increased toxicity) in patients treated with either thymidylate synthase (TS) inhibitors or folate antagonists (8,17,18). The gene discussed is TYMS; the disease is neoplasm.